Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 2 G2019S Mutations
Lianna Ishihara(University of Cambridge), Fayçal Hentati(National Institute of Neurology Mongi-Ben Hamida), Ryan J. Uitti(Jacksonville College), Nobutaka Hattori(Juntendo University Hospital), Zbigniew K. Wszołek(WinnMed), Liling Warren, Alexandra Dürr(Centre National de la Recherche Scientifique), Alexis Brice(Inserm), Lefkos Middleton(Imperial College Healthcare NHS Trust), Mériem Tazir(Hôpital Mustapha Pacha), Cyrus P. Zabetian(University of Washington), Tatiana Foroud(University of Southern California), Matthew J. Farrer(University of Florida), Rachel A. Gibson(GlaxoSmithKline (United Kingdom)), Rim Amouri(Tunis University), Suzanne Lesage(Centre National de la Recherche Scientifique), Ray L. Watts(University of Alabama at Birmingham), David Leppert, William C. Nichols(Cincinnati Children's Hospital Medical Center), Alida Griffith(University of Namur)
Cited by 103
Related Papers
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
|Nature Genetics|2000|2k
PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy
|The Journal of Cell Biology|2010|1.9k